Antimicrobial susceptibility among bacterial isolates from ICU and non-ICU settings and different age groups: Results from the Tigecycline Evaluation and Surveillance Trial in North America

Journal of Chemotherapy

Volumn 21, Issue 1, 2009, Pages 16-23

  Low, Donald E ^a   Markovic, M J ^b   Dowzicky, M J ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b St Vincent Charity Hospital   (United States)

^c PFIZER INC   (United States)

Author keywords

Age groups; Antimicrobial resistance; Bacterial infections; Intensive care unit; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG MECHANISM; ENTEROCOCCUS FAECIUM; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; NORTH AMERICA; STAPHYLOCOCCUS AUREUS;

EID: 63049132163     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.1.16     Document Type: Article

References (29)

1. Lodise TP, McKinnon PS. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005; 52: 113-122.
2. The Brooklyn Antibiotic Resistance Task Force. The cost of antibiotic resistance: effect of resistance among Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa on length of hospital stay. Infect Control Hosp Epidemiol 2002; 23: 106-108.
3. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41: 923-929.
4. Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002; 136: 834-844.
5. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY antimicrobial surveillance program (1997-2002). Diagn Microbiol Infect Dis 2004; 50: 59-69.
6. Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, document M100-S16. 2006. Clinical and Laboratory Standards Institute, Wayne, PA.
7. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6. 2003. National Committee for Clinical Laboratory Standards, Wayne, PA.
8. Wyeth Pharmaceuticals. Tygacil Product Insert. 2005. Wyeth Pharmaceuticals, Philadelphia, PA. [Online.] http://www.wyeth.com/hcp/ tygacil. Accessed 2nd May 2008.
9. Styers D, Sheehan DJ, Hogan P, Sahm DF. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. Ann Clin Microbiol Antimicrob 2006; 5: 2 http://www.ann-clinmicrob.com/content/5/ 1/2.
10. Diekema DJ, Pfaller MA, Jones RN. Age-related trends in pathogen frequency and antimicrobial susceptibility of blood-stream isolates in North America: SENTRY Antimicrobial Surveillance Program, 1997-2000. Int J Antimicrob Agents 2002; 20: 412-418.
11. Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients: report from the Chemotherapy Alliance for Neutropenics and the Control of Emerging Resistance Program (North America). Diagn Microbiol Infect Dis 2006; 56: 75-82.
12. Tillotson GS, Draghi DC, Sahm DF, Tomfohrde KM, del Fabro T, Critchley IA. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study. J Antimicrob Chemother 2008; 62: 109-115.
13. Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother 2006; 50: 3479-3484.
14. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: S315-S332.
15. Gales AC, Sader HS, Fritsche TR. Tigecycline activity tested against 11808 bacterial pathogens recently collected from US medical centers. Diagn Microbiol Infect Dis 2008; 60: 421-427.
16. Zhanel GG, Decorby M, Nichol KA, Wierzbowski A, Baudry PJ, Karlowsky JA et al. Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006. Diagn Microbiol Infect Dis 2008; 62: 67-80.
17. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
18. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
19. Swoboda S, Fritz S, Martignoni ME, Feldhues RA, Hoppe-Tichy T, Buchler MW, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005; 56: 787-789.
20. Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006; 50: 4217-4219.
21. Gales AC, Jones RN, Forward KR, Liñares J, Sader HS, Verhoef J. Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY antimicrobial surveillance program (1997-1999). Clin Infect Dis 2001; 32(Suppl 2): 104-113.
22. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47: 1681-1688.
23. Jones ME, Draghi DC, Thornsberry C, Karlowsky JA, Sahm DF, Wenzel RP. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American Surveillance study (2000-2002). Ann Clin Microbiol Antimicrob 2004; 3: 14 www.ann-clinmicrob.com/content/3/1/14.
24. Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticus-baumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect 2007; 55: 49-57.
25. Sader HS, Jones RN, Stilwell MG, Dowzicky MJ, Fritsche TR. Tigecycline activity tested against 26,474 bloodstream infection isolates: a collection from 6 continents. Diagn Microbiol Infect Dis 2005; 52: 181-186.
26. Karageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62: 45-55.
27. Winokur PL, Canton R, Casellas JM, Legakis N. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. Clin Infect Dis 2001; 32 (Suppl 2): S94-S103.
28. Paterson DL, Bonomo RA. Extended-spectrum p-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
29. Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ, Jones RN. Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. Diagn Microbiol Infect Dis 2005; 52: 209-213.